ArticlePloS one2021

Initial dose reduction of enzalutamide does not decrease the incidence of adverse events in castration-resistant prostate cancer.

Shunsuke Tsuzuki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.